8-K: Cartesian Therapeutics Reports Full Year 2023 Results and Provides Business Update

Cartesian Therapeutics announced its full year 2023 financial results, provided a business update, and highlighted key milestones for its mRNA CAR-T cell therapy programs.

Summary

• Cartesian Therapeutics reported its financial results for the year ended December 31, 2023, and provided updates on its clinical programs.
• The company has approximately $118.3 million in pro forma cash, cash equivalents, and restricted cash as of December 31, 2023, which is expected to fund operations into the second half of 2026.
• Topline data from the Phase 2b study of Descartes-08 in myasthenia gravis (MG) is expected in mid-2024.
• A Phase 2 study of Descartes-08 in systemic lupus erythematosus (SLE) is planned for the first half of 2024, with additional Phase 2 basket studies in other autoimmune indications in the second half of 2024.
• The company's IND application for Descartes-15, a next-generation mRNA CAR-T product, has been cleared, and a Phase 1 dose escalation study is planned.
• Research and development expenses were $71.8 million for 2023, slightly down from $72.4 million in 2022.
• General and administrative expenses increased to $40.6 million in 2023 from $23.9 million in 2022, primarily due to stock compensation, personnel expenses, and merger-related fees.
• The company reported a net loss of $(219.7) million for 2023, compared to a net income of $35.4 million in 2022, with a net loss per share of $(1.66).

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company has a strong cash position and is making progress on its clinical programs, the significant net loss and planned reverse stock split temper the positive aspects. The company is making progress but is still in a high risk phase.

Positives

• The company has a strong cash position of $118.3 million, expected to fund operations into the second half of 2026.
• The Phase 2b trial of Descartes-08 in myasthenia gravis is progressing, with topline data expected mid-2024.
• The company is expanding its pipeline with a Phase 2 study of Descartes-08 in systemic lupus erythematosus planned for the first half of 2024.
• The IND clearance for Descartes-15 allows for the initiation of a Phase 1 study.
• Positive long-term follow-up data from the Phase 2a study of Descartes-08 in myasthenia gravis showed durable depletion of autoantibodies and clinical improvements.
• Descartes-08 has been granted Orphan Drug Designation by the FDA for the treatment of MG.
• The company is transitioning to a new 20,000 square foot cGMP compliant facility in Frederick, Maryland.

Negatives

• The company reported a significant net loss of $(219.7) million for 2023, compared to a net income of $35.4 million in 2022.
• General and administrative expenses increased substantially to $40.6 million in 2023, up from $23.9 million in 2022.
• The company is planning a reverse stock split, which can sometimes be viewed negatively by investors.

Risks

• The company's clinical trials are subject to uncertainties, including the timing and outcome of data readouts.
• There are risks associated with the company's reliance on third parties to conduct clinical trials.
• The company faces risks related to its ability to protect its proprietary technology and intellectual property.
• The company has a history of recurring losses from operations and negative cash flows.
• The company's stock price is subject to substantial fluctuation.
• The company is subject to risks related to geopolitical conflicts and pandemics.

Future Outlook

The company expects its cash resources to support planned operations into the second half of 2026, including the Phase 3 study of Descartes-08. They anticipate several value-creating milestones throughout the year, including topline data from the Phase 2b trial in MG and initiation of Phase 2 studies in SLE and other autoimmune indications.

Management Comments

• With several potentially value-creating milestones anticipated throughout the year ahead, we are making strong progress in our mission to deliver innovative cell therapies to patients suffering from autoimmune diseases, said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian.
• We believe this represents the most advanced and only randomized, controlled Phase 2 trial of a chimeric antigen receptor (CAR) T-cell therapy for autoimmune diseases.
• Supported by the clinical dataset from the previously completed Phase 2a study in patients with MG, we believe that Descartes-08, which we engineer with our novel mRNA engineered CAR-T (mRNA CAR-T) technology, does not require preconditioning chemotherapy, and is expected to be administered in an outpatient setting, could serve as the first CAR-T cell therapy to reach patients with autoimmune diseases.

Industry Context

This announcement highlights the growing interest and investment in mRNA-based cell therapies for autoimmune diseases. Cartesian's focus on outpatient administration without preconditioning chemotherapy positions them as a potential leader in this space, differentiating them from traditional CAR-T therapies that often require hospitalization and chemotherapy.

Comparison to Industry Standards

• Cartesian's approach of using mRNA CAR-T technology without preconditioning chemotherapy is a significant differentiator compared to traditional CAR-T therapies, such as those developed by Gilead (Yescarta) and Novartis (Kymriah), which are primarily used in oncology and require preconditioning chemotherapy.
• The company's focus on autoimmune diseases is also a departure from the majority of CAR-T development, which is heavily concentrated in oncology. Companies like Kyverna Therapeutics are also exploring CAR-T therapies for autoimmune diseases, but Cartesian's mRNA approach is unique.
• The $118.3 million cash position is relatively strong for a clinical-stage biotech company, providing a runway into the second half of 2026, which is comparable to other companies at a similar stage of development.
• The net loss of $(219.7) million is significant, but not uncommon for a company investing heavily in research and development. This is similar to other biotech companies in the clinical stage, such as those developing novel therapies.

Stakeholder Impact

• Shareholders will be impacted by the planned reverse stock split and the potential for future capital raises.
• Patients with autoimmune diseases may benefit from the company's development of novel mRNA CAR-T therapies.
• Employees may be impacted by the transition of the corporate headquarters to Frederick, Maryland.

Next Steps

• The company will hold a special meeting of stockholders on March 27, 2024, to approve the conversion of preferred stock and a reverse stock split.
• Topline data from the Phase 2b study of Descartes-08 in myasthenia gravis is expected in mid-2024.
• The company plans to initiate a Phase 2 study of Descartes-08 in systemic lupus erythematosus in the first half of 2024.
• Phase 2 basket studies in additional autoimmune indications are planned for the second half of 2024.
• The company will initiate a Phase 1 dose escalation study of Descartes-15.
• The company will transition its corporate headquarters to Frederick, Maryland.

Key Dates

Keywords

mRNA CAR-T, Cell Therapy, Autoimmune Diseases, Myasthenia Gravis, Systemic Lupus Erythematosus, Descartes-08, Descartes-15, Clinical Trials, Biotechnology, Financial Results